English中文

Offstream
news


COVID-19 pandemic

A compromise is reached regarding a COVID-19 vaccine intellectual property waiver for developing countries. According to the compromise, developing countries which have exported less than 10% of the world's COVID-19 vaccine doses in 2021 do not need to seek consent from the owner of the patent before authorising the vaccine. The patent waiver does not apply to other COVID-19-related pharmaceutical products.

Sources:  Politico


Changes

  1. A compromise is reached about COVID-19 vaccine intellectual property waiver for developing countries. According to the compromise, developing countries which have exported less than 10% of the world's COVID-19 vaccine doses in 2021 need not seek consent from the owner of the patent before authorising the vaccine. The patent waiver does not apply to other COVID-19-related pharmaceutical products.
  2. A compromise is reached regarding a COVID-19 vaccine intellectual property waiver for developing countries. According to the compromise, developing countries which have exported less than 10% of the world's COVID-19 vaccine doses in 2021 do not need to seek consent from the owner of the patent before authorising the vaccine. The patent waiver does not apply to other COVID-19-related pharmaceutical products.

Related